Gland Pharma Share Price Target (2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030) | Gland Pharma Ltd Businesses, Fundamentals, Future and more.
Are you looking for a Gland Pharma Share Price Target? If yes, then you are at the right place.
In this post, we will detail Gland Pharma’s analysis because investors are predicting that it can give good long-term returns. And recently, in Gland Pharma Share, we have seen a good uptrend.
As we know, Gland Pharma is a large capitalization stock, and investing in it is a little bit less risky than any mid-cap or small-cap stock. This share has given -9.11% returns from November 2020 to August 2023, In this situation, It will be good to invest in it. we will know everything in this post.
About Gland Pharma
Gland Pharma Ltd is a leading pharmaceutical company in India that is known for its advanced research & development and manufacturing of high-quality generic injectables. The company was incorporated in 1978, As a leader in the pharma industries, especially in the area of injectable formulations.
Gland Pharma is primarily engaged in the production of a wide range of injectables like ampoules, pre-filled syringes, vials, lyophilized vials, and other specialty formulations. The product of the company Cater to several therapeutic areas like, oncology, cardiology, nephrology, anti-infective, and more.
Also Read – HAL Share Price Target
Gland Pharma Fundamentals
| Market Cap. | ₹22,112 Cr |
| P/E ratio | 29.64 |
| EPS | 45.29 |
| ROE | 10.33% |
| Dividend Yield | NA |
| Book Value | 483.22 |
| Debt | ₹4.45 Cr |
| Debt To Equity | 0 |
- ROE (Return on Equity): A healthy ROE of 10.33% suggests that the company efficiently generates profit using shareholders’ equity, which is a positive sign.
- P/E Ratio (TTM): The P/E ratio of 29.64 indicates that investors are willing to pay approximately 29.64 times the company’s earnings per share. This suggests moderate valuation and further context is needed to determine if it’s reasonable.
- EPS (TTM): An EPS of 45.29 signifies the company’s earning capacity per share. This high EPS is a positive indication of profitability.
- Dividend Yield: The dividend yield information is unavailable, meaning the company’s dividend distribution isn’t disclosed in this data.
- Industry P/E: Comparing Gland Pharma’s P/E to the industry average (26.61) suggests that it might be trading at a slightly higher valuation than its industry peers.
- Book Value: The book value per share (483.22) signifies the net asset value. A higher book value indicates solid underlying assets.
- Debt to Equity: A debt-to-equity ratio of 0.00 implies that the company has zero debt relative to its equity. This reflects a strong financial position with no significant debt burden.
Gland Pharma Financial Trends
If we talk about the Revenue and Profit of Gland Pharma then –
Its revenue in 2020 was ₹ 2,633 Cr and its profit was ₹ 773 Cr. There was a revenue of ₹ 3,463 Cr in 2021 and a profit of ₹ 997 Cr. In the same 2022, there was a profit of ₹ 1,212 Cr with a revenue of ₹ 4,401 Cr. And this year i.e. in 2023 there has been a profit of ₹ 781 Cr with a revenue of ₹ 3,625 Cr.
Gland Pharma Share Price Target Table
| Year | Highest Return | Average Return | Lowest Return |
|---|---|---|---|
| Gland Pharma Share Price Target 2023 | ₹1707 | ₹1675 | ₹1659 |
| Gland Pharma Share Price Target 2024 | ₹1810 | ₹1742 | ₹1709 |
| Gland Pharma Share Price Target 2025 | ₹1918 | ₹1812 | ₹1760 |
| Gland Pharma Share Price Target 2026 | ₹2033 | ₹1884 | ₹1813 |
| Gland Pharma Share Price Target 2027 | ₹2155 | ₹1960 | ₹1867 |
| Gland Pharma Share Price Target 2028 | ₹2285 | ₹2038 | ₹1923 |
| Gland Pharma Share Price Target 2029 | ₹2422 | ₹2119 | ₹1981 |
| Gland Pharma Share Price Target 2030 | ₹2567 | ₹2204 | ₹2040 |
Fot more details about Gland Pharma Ltd share, you can watch this video –
Also Read – Gold Line Share Price Target
Gland Pharma Share Price Target 2023
Gland Pharma Share has given good returns in the last 6 months of 29.48% while in the last 1 year, the return was -27%. Due to its good quarterly earnings results, it is seeing a good uptrend recently. It is predicted by analysts that the average Gland Pharma Share Price Target 2023 can be INR 1675 while the highest price can be 1707 and the lowest will be INR 1659.
Gland Pharma Share Price Target 2024
By analyzing its past performance, it is speculated that the share can show a small decline. Well, the fundamentals of the share are improving, and the share can give a little bit of good returns. The P/E ratio is 29.64 while its ROE is 10.33%, which is considered good. Anyway, according to its historical data, the average, highest, and lowest Gland Pharma Share Price Target 2024 can be INR 1742, INR 1810, and INR 1709 respectively.
Gland Pharma Share Price Target 2025
The profit of this company in 2023 is ₹781 crore, while in 2022 the profit was ₹1,212 crore. And it is being expected that, in 2023 the profit of the company can increase by 5% and its revenue too. The analyst is predicting that the average Gland Pharma Share Price Target 2025 can be INR 1812 and its highest and lowest prices can be INR 1918 and INR 1760 respectively. Since the financial trends of the company are fluctuating, in the 2nd quarter of 2023 the company made a huge profit, which is good.
Gland Pharma Share Price Target 2030
In the long run, Gland Pharma may be a good investment but, As it has given poor returns for a few years hence, investing in it is a bit worrying. So considering all these things and its past performance, it is being concluded that the average price can be INR 2204 while the highest and lowest Gland Pharma Share Price Target 2030 can be INR 2567 and INR 2040 respectively.
Conclusion
That’s it in this article, we have tried our best to tell you about Gland Pharma share very well. So friends, if you are investing in shares only after seeing the Gland Pharma share price Target, then do not do this. Because there are many reasons behind the rise and fall of the Stock price.
I hope you got to learn a lot from this Gland Pharma Share Price Target 2023, 2024, 2025, 2026, and 2030 article. And you will be able to decide by yourself whether you have to invest in this stock or not. If you have any queries, please ask in the comment box we will try to solve your issue by providing a better solution.
FAQs
Is Gland Pharma a debt-free company?
No, Gland Pharma is not a debt-free company, Currently, this company has a small debt of ₹4.45 crore and its debt-to-equity ratio is 0.
Who is the Chairman of Gland Pharma?
Mr. Yiu Kwan Stanley Lau is the present chairman of Gland Pharma.
Also Read –
